Last reviewed · How we verify
Meningococcal A+C vaccine
This vaccine stimulates the immune system to produce antibodies against Neisseria meningitidis serogroups A and C polysaccharide antigens.
This vaccine stimulates the immune system to produce antibodies against Neisseria meningitidis serogroups A and C polysaccharide antigens. Used for Prevention of meningococcal disease caused by Neisseria meningitidis serogroups A and C.
At a glance
| Generic name | Meningococcal A+C vaccine |
|---|---|
| Sponsor | Sanofi Pasteur, a Sanofi Company |
| Drug class | Polysaccharide conjugate vaccine |
| Target | Neisseria meningitidis serogroups A and C capsular polysaccharides |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
The vaccine contains purified polysaccharide capsules from meningococcal serogroups A and C conjugated to a protein carrier, which enhances immunogenicity and T-cell dependent responses. Upon administration, it triggers both humoral and cellular immune responses, leading to the production of protective antibodies (primarily IgG) against these bacterial serogroups. This provides immunity against invasive meningococcal disease caused by these two serogroups.
Approved indications
- Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A and C
Common side effects
- Injection site pain/tenderness
- Injection site erythema
- Injection site swelling
- Fever
- Myalgia
- Headache
Key clinical trials
- A Study to Assess the Experimental Malaria Vaccines R78C and RH5.1 With Matrix-M in Combination With R21/Matrix-M (PHASE2)
- Phase IV Clinical Study of Immunogenicity of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) (PHASE4)
- Long-Term PF-06651600 for the Treatment of Alopecia Areata (PHASE3)
- A Study to Evaluate Safety, Reactogenicity, and Immune Response of GVGH iNTS-TCV Vaccine Against Invasive Nontyphoidal Salmonella Disease and Typhoid Fever in Infants (PHASE2)
- Study of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Given With Routine Pediatric Vaccines in Healthy Infants and Toddlers in India and the Republic of South Africa (PHASE3)
- Long-Term Immunogenicity of the altSonflex1-2-3 Shigella Vaccine in African Children (PHASE2)
- Assessment of Immunogenicity, Reactogenicity and Safety of the Drug GNG-DE in Comparison With the Reference Drug (PHASE3)
- MenB-FHbp or MenACWY-TT/MenB-FHbp Vaccine in MenB-4C Primed Young Adults (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Meningococcal A+C vaccine CI brief — competitive landscape report
- Meningococcal A+C vaccine updates RSS · CI watch RSS
- Sanofi Pasteur, a Sanofi Company portfolio CI